Treatment of ovarian cancer with a tropism modified oncolytic adenovirus

Gerd J. Bauerschmitz, John T. Lam, Anna Kanerva, Kaori Suzuki, Dirk M. Nettelbeck, Igor Dmitriev, Victor Krasnykh, Galina V. Mikheeva, Mack N. Barnes, Ronald D. Alvarez, Peter Dall, Ramon Alemany, David T. Curiel, Akseli Hemminki

Research output: Contribution to journalArticlepeer-review

149 Scopus citations


Ad5-Δ24RGD is an adenovirus that is selectively replication competent in cells defective in the Rb/p16 pathway, such as ovarian cancer cells. The fiber of Ad5-Δ24RGD contains an integrin binding RGD-4C motif, allowing Coxsackie adenovirus receptor-independent infection of cancer cells. Oncolysis of cell lines was similar to that of a wild-type control, and replication in primary tumor material was shown using a novel three-dimensional spheroid model. Finally, an orthotopic murine model of peritoneally disseminated ovarian cancer was used to test i.p. administration to tumor-bearing animals. Injection of the agent resulted in eradication of i.p. disease, whereas control animals expired (P < 0.0001). These results suggest that Ad5-Δ24RGD could be useful for treatment of ovarian cancer in humans.

Original languageEnglish
Pages (from-to)1266-1270
Number of pages5
JournalCancer research
Issue number5
StatePublished - Mar 1 2002


Dive into the research topics of 'Treatment of ovarian cancer with a tropism modified oncolytic adenovirus'. Together they form a unique fingerprint.

Cite this